HRT after endometrial ablation: the uterus is still part of the decision
Endometrial ablation treats the uterine lining; it does not remove the uterus. A later systemic HRT consultation still needs the procedure report, any remaining bleeding history, and an explicit plan for endometrial protection.
Endometrial ablation does not make a person equivalent to someone who has had a hysterectomy. The uterus remains, even though its lining has been treated and periods may change or stop. When systemic menopause hormone therapy is considered later, the clinician still needs to address endometrial protection and interpret any bleeding against the ablation record; a history of no periods is not proof that all uterine lining is absent.123
That distinction is easy to lose on an intake form. “No periods since ablation” describes a bleeding pattern. “No uterus” describes surgery. They lead to different questions about systemic estrogen, progestogen, and evaluation of new bleeding. The hysterectomy guide owns the removed-uterus decision; this article addresses the intact uterus after lining treatment.
Start with the operation, not the calendar
FDA describes endometrial ablation as a procedure intended to destroy or remove the uterine lining to reduce heavy bleeding. It is not sterilization, and pregnancy may still occur afterward.1 The technique and degree of lining change can differ. A patient may have lighter periods, no noticeable periods, or persistent or recurrent bleeding. None of those outcomes independently documents that the uterus was removed.
The useful record is the operative report: date, procedure or device, findings, whether another operation occurred, and what the clinician said about follow-up. If the person also had a tubal procedure, hysteroscopy, fibroid treatment, or later surgery, name each separately. “Ablation” alone does not tell a new HRT prescriber the entire uterine history.
| History item | What it can clarify | What it cannot prove |
|---|---|---|
| Ablation procedure report | How the lining was treated and what the operator observed | That no endometrium can ever remain |
| Bleeding record since surgery | Whether bleeding stopped, continued or returned | That systemic estrogen needs no endometrial plan |
| Other pelvic procedures | Whether the uterus, cervix or ovaries were later changed | That 'ablation' and 'hysterectomy' are interchangeable |
Why systemic HRT still needs an endometrial question
ACOG’s general menopause-hormone guidance explains why systemic estrogen is usually paired with a progestogen when the uterus is present: the progestogen protects the endometrium from estrogen-driven thickening.3 The British Menopause Society’s current clinician tool specifically addresses people with prior ablation and recommends considering combined HRT rather than assuming ablation removed the need for protection.2 That is professional UK guidance, not a prescription for a named U.S. product.
The decisive question at a U.S. consultation is therefore not “Did ablation stop my period?” It is “What uterine tissue and bleeding history do we need to account for with this exact proposed systemic product?” The prescriber can then explain the rationale for any hormone combination, the product’s labeled use, and who will assess future symptoms. Treomark does not select a regimen or infer it from an online procedure description.
Local vaginal estrogen used for a local symptom is a different treatment question from systemic estrogen used for hot flashes or other whole-body goals. The route and indication should be named before importing a systemic-HRT rule into a local-product conversation. Similarly, contraceptive protection is separate: FDA cautions that ablation itself does not prevent pregnancy.1
Make post-ablation bleeding interpretable
A person whose periods disappeared after ablation may later have spotting, a new pattern of bleeding, or symptoms that are difficult to date against a cycle. The history matters even if they are not yet using HRT. Record when the change was first noticed, whether bleeding was present before HRT, the exact product in use, and any earlier evaluation. This is a history for the clinician, not a home method to classify the cause.
The unscheduled-bleeding guide explains why a planned withdrawal pattern is different from unexpected or persistent bleeding during HRT. Prior ablation adds context, but it does not make new bleeding automatically expected or harmless. Nor should someone infer that a lack of bleeding proves endometrial protection is adequate.
If an HRT clinic says an ablation means “you no longer need progesterone,” ask what source and operative facts support that statement for the proposed systemic product. If the clinic instead proposes a combination, ask which part is intended to address menopausal symptoms and which part addresses the intact-uterus issue. A clear answer names the purpose of each component without treating every post-ablation patient as identical.
A concise record to bring to the visit
Bring the ablation operative report, any later pelvic-surgery reports, a history of bleeding since the procedure, current medicines, and the symptom or goal that prompted the HRT inquiry. If another clinician previously evaluated bleeding, include that result. Ask whether the proposed product is systemic or local, how its label fits the goal, how endometrial protection will be addressed, and which clinician owns a new bleeding concern.
The hormone-therapy provider directory can help compare South Florida practices. A useful provider conversation translates the actual operation and subsequent history into a documented plan; it does not convert “periods stopped” into a shorthand for “uterus absent.”
Sources
- U.S. Food and Drug Administration. Endometrial ablation for heavy menstrual bleeding. Ablation destroys or removes uterine lining rather than the uterus; bleeding outcomes vary, and pregnancy remains possible. Accessed .
- British Menopause Society. Progestogens and endometrial protection, May 2026. Current UK clinician tool specifically addresses systemic HRT after ablation and the continuing need to consider progestogen/endometrial protection; not a U.S. product label or personal regimen. Accessed .
- American College of Obstetricians and Gynecologists. Hormone therapy for menopause. Explains the general systemic-estrogen and intact-uterus endometrial-protection distinction. Accessed .